Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Five pharmaceuticals featured on Time’s list of top inventions alongside other medical breakthroughs

By Brian Buntz | November 6, 2023

vector medical and health icons and business network background concept

[Adobe Stock]

Time magazine’s most recent roundup of 200 inventions included an array of product types, spanning household gadgets and AI applications. Five distinct pharmaceuticals also made the list, not counting a shipping container for biologics and a vaccine for bees. Among the notable pharmaceutical advances on the list are a novel postpartum depression drug, a novel Alzheimer’s therapy, the first FDA-approved RSV vaccine, a blockbuster drug for diabetes and obesity that has driven record-breaking sales for Novo Nordisk. Outside of pharmaceuticals, other medical products that made Time’s list include advanced prosthetic limbs and portable diagnostic devices. Read on to see which pharmaceutical products won the attention of one of the most influential magazines in the U.S.

Zurzuvae, a new PPD treatment option

Zuranolone

Zuranolone molecule image from PubChem

Among Time’s top pharma inventions 2023 is Zurzuvae, which won FDA approval in August 2023 as a treatment option for postpartum depression (PPD). Before the approval, PPD options were generally limited to traditional antidepressants and Zulresso (brexanolone), a structurally similar drug to Zurzuvae that requires a 60-hour intravenous infusion. By contrast, zuranolone is an oral drug.

Arexvy, the first FDA-approved RSV vaccine

In May, GSK’s Arexvy became the first RSV vaccine to win FDA approval. Specifically covering adults 60 and older, Arexvy remains the market-leading RSV vaccine. GSK aims to expand approval of its Arexvy to adults aged 50-59 based on encouraging phase 3 data showing comparable immune response to those 60 and up.

Type 2 diabetes and obesity megablockbuster semaglutide

OzempicFirst approved as Ozempic for type 2 diabetes management in 2017, Novo Nordisk’s semaglutide has emerged as a juggernaut more recently. Two years later, the FDA approved an oral version of the drug for the same indication. In 2020, FDA expanded Ozempic’s use to include cardiovascular risk reduction in patients with type 2 diabetes. An Ozempic approval in 2022 followed for higher-dose semaglutide for increased glycemic control for the same patient population. But the drug’s FDA approval as Wegovy in 2021 for chronic weight management

has catalyzed a strong surge in sales demand, helping make Novo Nordisk Denmark’s biggest company.

Tzield, first disease-modifying therapy for type 1 diabetes

Also earning its place on Time’s Top Pharma Inventions 2023 is Tzield (teplizumab-mzwv), which can delay the onset of type 1 diabetes. A humanized monoclonal antibody that targets CD3 on T cells, the drug from Provention Bio is the first disease-modifying therapy for type 1 diabetes. Its price tag of nearly $200,000 for the full 14-day course of treatment has raised affordability concerns. Provention has partnered with Sanofi to commercialize the therapy and has developed an access program.

Leading light in Alzheimer’s management

Conceptual illustration of neuron cells with glowing link knots in abstract dark space, high resolution 3D illustration

Conceptual representation of neurons [Adobe Stock]

Lecanemab (Leqembi) from Eisai and Biogen is not the first monoclonal antibody to win FDA approval. That distinction goes to Aduhelm (aducanumab), which won accelerated FDA approval on June 7, 2021​. By contrast, lecanemab won accelerated approval in January 2023. Lecanemab’s phase 3 clinical trial data was stronger than aducanumab’s and the drug appears to have a more favorable risk-benefit profile. The Clarity AD trial demonstrated a 27% slower decline in the primary endpoint, with highly statistically significant outcomes. The data helped pave the way for traditional FDA approval in July 2023. GlobalData expects the drug to generate $12.9 billion in sales by 2028.

Ember Cube offers a sustainable option for cold-chain biologics transport

Ember cube

Ember Cube

Cardinal Health partnered with temperature control firm Ember Technologies to develop the Ember Cube, a reusable self-refrigerated shipping container, to distribute temperature-sensitive biologics. The product maintains precise temperature control and provides real-time tracking of metrics such as temperature and location via cloud-connected IoT sensors. Cardinal Health sees potential in the Ember Cube to reduce waste from traditional cold-chain shippers while enabling greater visibility into products in transit.

The first vaccine for insects

A new vaccine for American foulbrood disease in honey bees has won conditional licensure from the USDA, marking the first vaccine for insects. The vaccine from Dalan Animal Health is not injected. Instead, it’s a novel oral vaccine that is mixed with queen candy — a sugary food for the queen bee. Afterwards, when the queen ingests this mixture, it supports the transfer of the vaccine’s protective elements to her eggs. The vaccine provides protection for the hive as the vaccinated queen’s eggs develop into larvae that are innately equipped to combat the foulbrood bacteria that causes the contagious and often fatal disease. With foulbrood infecting up to 25% of hives in some areas and managed hives critical for pollinating one-third of U.S. fruits and vegetables, the widespread adoption of the vaccine could support agricultural health and the sustainability of beekeeping practices.


Filed Under: Biologics, Metabolic disease/endicrinology, Neurological Disease
Tagged With: Alzheimer’s treatments, biologics transport, diabetes management drugs, FDA approvals, medical breakthroughs, pharmaceutical innovations, vaccine development
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
GSK sees latest Nucala approval as the first shot in a long-term war to deconstruct and personalize COPD treatment
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE